Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model

Objectives: Radioimmunotherapy (RIT) has emerged as a potential treatment option for multiple myeloma (MM). In humans, a dosimetry study recently showed the relevance of RIT using an antibody targeting the CD138 antigen. The therapeutic efficacy of RIT using an anti-CD138 antibody coupled to 213Bi,...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Nolwenn eFichou, Sébastien eGouard, Catherine eMaurel, Jacques eBarbet, Ludovic eFerrer, Alfred eMorgenstern, Frank eBruchertseifer, Alain eFaivre-Chauvet, Edith eBigot-Corbel, François eDavodeau, Joelle eGaschet, Michel eChérel
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2015-11-01
Σειρά:	Frontiers in Medicine
Θέματα:	Multiple Myeloma Radioimmunotherapy CD138 Lutetium-177 bismuth-213
Διαθέσιμο Online:	http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00076/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!